Research Models
Selected Results
3 Models
Name | Other Names | Strain Name | Genetic Background | Gene | Mutation | Modification Info | Modification | Disease | Neuropathology | Behavior/Cognition | Other Phenotype | Availability | Primary Paper | Visualization | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mouse Models (3) |
|||||||||||||||
APOE2 Humanized Knock-in | B6.129P2-Apoetm1(APOE*2)Mae N9 | C57BL/6 | APOE | Targeted gene replacement of the endogenous murine APOE gene with the human APOE2 allele. Targeting construct included exons 2-4 of APOE2. | APOE: Knock-In | Alzheimer's Disease | Unknown. | Unknown. | Characteristics of type III hyperlipoproteinemia. Plasma cholesterol and triglyceride levels 2-3x higher than APOE3 mice. Impaired clearance of very-low-density lipoprotein (VLDL) particles. Atherosclerotic plaques. | Taconic: Stock# 1547-F and 1547-M | Sullivan et al., 1998 | Yes | |||
APOE3 Humanized Knock-in | B6.129P2-Apoetm2(APOE*3)Mae N8 | 129 x C57BL/6; back-crossed to C57BL/6 | APOE | Targeted replacement of the endogenous mouse APOE gene with the human APOE3 allele. Targeting vector contained exons 2-4 of human APOE3. | APOE: Knock-In | Alzheimer's Disease | Unknown. | Unknown. | On a standard diet, homozygous mice have normal cholesterol and triglyceride levels, but are more susceptible than wild-type animals to diet-induced atherosclerosis. | Taconic: Stock# 1548-F and 1548-M | Sullivan et al., 1997 | Yes | |||
APOE4 Humanized Knock-in | B6.129P2-Apoetm3(APOE*4)Mae N8 | 129 x C57BL/6, back-crossed to C57BL/6 | APOE | Targeted replacement of the endogenous murine APOE gene with the human APOE4 allele; targeting construct contained exons 2–4 of APOE4. | APOE: Knock-In | Alzheimer's Disease | Unknown. | Unknown. | Increased risk of atherosclerosis. Elevated cholesterol, APOE, and APOB-48 on a high fat diet. | Taconic: Stock# 1549-F or 1549-M | Knouff et al., 1999 | No |
2 Visualizations
AD-related Research Models
Phenotypes Examined
- Plaques
- Tangles
- Neuronal Loss
- Gliosis
- Synaptic Loss
- Changes in LTP/LTD
- Cognitive Impairment
When visualized, these phenotypes will distributed over a 18 month timeline demarcated at the following intervals: 3mo, 6mo, 9mo, 1yr, 15mo, 18mo+.
APOE2 Targeted Replacement
Observed
Absent
No Data
-
Plaques at
No data.
-
Tangles at
No data.
-
Neuronal Loss at
No data.
-
Gliosis at
No data.
-
Synaptic Loss at
No data.
-
Changes in LTP/LTD at
No data.
-
Cognitive Impairment at
No data.
Genes | Mutations | Modification | Disease | Neuropathology | Behavior/Cognition |
---|---|---|---|---|---|
APOE | APOE: Knock-In | Alzheimer's Disease | Unknown. |
Unknown. |
APOE3 Targeted Replacement
Observed
Absent
No Data
-
Plaques at
No data.
-
Tangles at
No data.
-
Neuronal Loss at
No data.
-
Gliosis at
No data.
-
Synaptic Loss at
No data.
-
Changes in LTP/LTD at
No data.
-
Cognitive Impairment at
No data.
Genes | Mutations | Modification | Disease | Neuropathology | Behavior/Cognition |
---|---|---|---|---|---|
APOE | APOE: Knock-In | Alzheimer's Disease | Unknown. |
Unknown. |